Journal
ADVANCED DRUG DELIVERY REVIEWS
Volume 61, Issue 6, Pages 478-486Publisher
ELSEVIER
DOI: 10.1016/j.addr.2009.03.008
Keywords
Nanotechnology; Nanopharmaceuticals; Nanoparticles; Dendrimers; Fullerenes; Carbon nanotubes; Metal oxide nanoparticles; Copper nanoparticles
Categories
Ask authors/readers for more resources
The lack of correlative and predictive models to assess acute and chronic toxicities limits the rapid preclinical development of new therapeutics. This barrier is due in part to the exponential growth of nanotechnology and nanotherapeutics, coupled with the lack of rigorous and robust screening assays and putative standards. It is a fairly simple and cost-effective process to initially screen the toxicity of a nanomaterial by using in vitro cell cultures; unfortunately it is nearly impossible to imitate a complimentary in vivo system. Small mammalian models are the most common method used to assess possible toxicities and biodistribution of nanomaterials in humans. Alternatively, Dania rerio, commonly known as zebrafish, are proving to be a quick, cheap, and facile model to conservatively assess toxicity of nanomaterials. (C) 2009 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available